Appraisal of Cardiac Ejection Fraction With Liver Disease Severity: Implication in Post–Liver Transplantation Mortality

Hepatology ◽  
2020 ◽  
Vol 71 (4) ◽  
pp. 1364-1380 ◽  
Author(s):  
Hye‐Mee Kwon ◽  
Young‐Jin Moon ◽  
Kyeo‐Woon Jung ◽  
Yong‐Seok Park ◽  
Kyoung‐Sun Kim ◽  
...  
Hepatology ◽  
2020 ◽  
Vol 72 (2) ◽  
pp. 783-783
Author(s):  
Won Ho Kim ◽  
Seong‐Mi Yang ◽  
Kook Hyun Lee

Author(s):  
R. M. Kurabekova ◽  
O. P. Shevchenko ◽  
O. M. Tsiroulnikova ◽  
N. P. Mozheyko ◽  
I. E. Tsiroulnikova ◽  
...  

Aim.Analysis of relationship between transforming growth factor beta-1 (TGF-β1) level in blood and liver disease severity before and after liver transplantation in early age children with congenital liver diseases.Materials and methods.The study included 135 pediatric patients aged from 2 to 73 months with end-stage liver disease.Results.The level of TGF-β1 in the blood of children with liver failure on average was lower than in healthy children of the same age. The cytokine level depended on the liver disease etiology: in patients with biliary atresia, biliary hypoplasia, Alagille syndrome, Byler disease and other diseases it was lower than that at Caroli disease when it did not differ from the level in healthy children. The level of cytokine in the blood plasma of patients was associated with the severity of hepatic fi brosis: in fi brosis of grade 1 and 4 it was lower than in fi brosis of grade 2 and 3. The liver transplantation from related living donor resulted in increase of TGF-β1 level in the blood plasma of patients regardless of the initial etiology and severity of the liver disease.Conclusion.The blood level of TGF-β1 refl ects liver disease severity in children with congenital liver diseases and may be used as a marker of liver function state before and after liver transplantation. 


Author(s):  
Jeniffer Danielle M. Dutra ◽  
Quelson Coelho Lisboa ◽  
Silvia Marinho Ferolla ◽  
Carolina Martinelli M. L. Carvalho ◽  
Camila Costa M. Mendes ◽  
...  

Abstract. Some epidemiological evidence suggests an inverse correlation between non-alcoholic fatty liver disease (NAFLD) frequency and vitamin D levels. Likewise, a beneficial effect of vitamin D on diabetes mellitus (DM) and insulin resistance has been observed, but this is an unsolved issue. Thus, we aimed to investigate the prevalence of hypovitaminosis D in a NAFLD Brazilian population and its association with disease severity and presence of comorbidities. In a cross-sectional study, the clinical, biochemical and histological parameters of 139 NAFLD patients were evaluated according to two different cut-off points of serum 25-hydroxyvitamin D levels (20 ng/mL and 30 ng/mL). The mean age of the population was 56 ± 16 years, most patients were female (83%), 72% had hypertension, 88% dyslipidemia, 46% DM, 98% central obesity, and 82% metabolic syndrome. Serum vitamin D levels were < 30 ng/mL in 78% of the patients, and < 20 ng/mL in 35%. The mean vitamin D level was 24.3 ± 6.8 ng/mL. The comparison between the clinical, biochemical and histological characteristics of the patients according to the levels of vitamin D showed no significant difference. Most patients with NAFLD had hypovitaminosis D, but low vitamin D levels were not related to disease severity and the presence of comorbidities.


2020 ◽  
Vol 1 (19) ◽  
pp. 39-46
Author(s):  
T. V. Pinchuk ◽  
N. V. Orlova ◽  
T. G. Suranova ◽  
T. I. Bonkalo

At the end of 2019, a new coronavirus (SARS-CoV-2) was discovered in China, causing the coronavirus infection COVID-19. The ongoing COVID-19 pandemic poses a major challenge to health systems around the world. There is still little information on how infection affects liver function and the significance of pre-existing liver disease as a risk factor for infection and severe COVID-19. In addition, some drugs used to treat the new coronavirus infection are hepatotoxic. In this article, we analyze data on the impact of COVID-19 on liver function, as well as on the course and outcome of COVID-19 in patients with liver disease, including hepatocellular carcinoma, or those on immunosuppressive therapy after liver transplantation.


1999 ◽  
Vol 384 (3) ◽  
pp. 259-263 ◽  
Author(s):  
C. A. Seiler ◽  
Jean-Francois Dufour ◽  
Eberhard L. Renner ◽  
Martin Schilling ◽  
Markus W. Büchler ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document